Neogen Corp focuses on food safety. Operations support long term growth
Neogen Corp specializes in food and animal safety, providing testing and diagnostic solutions to manage biological risks across global supply chains. The company offers a broad range of products for detecting pathogens and contaminants in food and feed, as well as solutions for animal health and biosecurity. Neogen's operations are closely linked to food industry trends and regulatory environments, with a focus on diversified revenue streams from consumables, instruments, and services, supporting long-term growth through continuous innovation and customer support.
NG2 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Neogen Corp (NG2) stock, including analyst price targets, future earnings, and revenue estimates. It highlights that analysts predict a maximum price of 11.42 EUR and a minimum of 9.66 EUR for NG2, and notes the company's past performance, upcoming earnings report, and financial metrics like EBITDA and net income.
Neogen Corp Actuals & Estimates (NASDAQ:NEOG)
This article provides an in-depth financial overview of Neogen Corporation (NASDAQ:NEOG), including its current stock price, historical performance, analyst forecasts, and detailed financial statements. It covers information on earnings, revenue, market capitalization, employee count, and EBITDA, along with guidance on how to buy the stock and relevant technical analysis ratings.
Neogen (NEOG) Stock Could Be 26.4% Undervalued After Texas And Florida Product Expansion
Neogen (NEOG) is considered to be 26.4% undervalued, with a fair value of $12 against its current price of $8.83, following its expansion of FIFRA Section 2(ee) recommendations for Prozap insect control products in Texas and Florida. The company's valuation narrative is supported by ongoing food supply chain complexities and increased demand for food safety solutions. However, challenges such as 3M Food Safety integration issues and softer Animal Safety demand still exist.
Neogen Corp (NEOG) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the major shareholders and institutional holdings of Neogen Corp (NEOG). It provides a breakdown of significant shareholders by proportion, types of shareholders such as investment advisors and hedge funds, and quarterly institutional shareholding data showing changes in shares held and proportion. Key institutional investors like BlackRock and Vanguard are listed, along with their respective holdings and recent changes.
Neogen Corp (NEOG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Neogen Corp (NEOG) by business segment and region, using data updated on April 6th. The "Culture Media & Other" segment contributes the largest proportion of revenue at 38.32%, followed by "Bacterial & General Sanitation" at 19.99%. Regionally, International revenue accounts for 50.85% and Domestic revenue for 49.15% of the total.
Neogen expands FIFRA 2(ee) recommendations to counter threat
Neogen, a leader in food and animal safety solutions, has expanded the availability of FIFRA Section 2(ee) recommendations for Prozap® Insectrin X Concentrate and Prozap® Screw Worm and Ear Tick Aerosol in Texas and Florida. These recommendations provide ranchers and livestock owners with additional options for fly management, particularly in response to the New World screwworm (NWS) threat. The company emphasizes the importance of vigilance and integrated fly control programs for managing ongoing insect challenges and emerging concerns.
Neogen adds Texas, Florida fly-control tools for New World screwworm
Neogen Corporation has expanded the availability of its FIFRA Section 2(ee) recommendations for Prozap® Insectrin X Concentrate and Prozap® Screw Worm and Ear Tick Aerosol in Texas and Florida. These products will help ranchers, livestock producers, and horse owners combat the New World Screwworm (NWS) through enhanced fly management programs. The move comes as industry attention focuses on prevention and control of NWS, which was largely eradicated decades ago but has seen increased concern recently.
Does Expanded Prozap Use in Texas and Florida Signal a Deeper Shift in Neogen's (NEOG) Animal Health Strategy?
Neogen Corporation has expanded the availability of its Prozap Insectrin X Concentrate and Prozap Screw Worm and Ear Tick Aerosol in Texas and Florida, offering more options for livestock and horse owners in pest management. This move, while incremental, supports Neogen's Animal Safety segment amidst ongoing challenges with Food Safety integration and broader economic headwinds. The company has raised its fiscal 2026 revenue guidance, suggesting cautious optimism, but the long-term impact on its investment narrative remains dependent on resolving integration issues and market pressures.
Neogen Corp (NEOG) Valuation: PE, PB & Fair Value Analysis
This article provides a brief valuation analysis for Neogen Corp (NEOG), stating its current valuation score and its ranking within the Healthcare Equipment & Supplies industry. It highlights the company's current P/E ratio and notes that P/B, P/S, and P/CF data have not yet been disclosed by the company.
Neogen Corp (NEOG) Risk Assessment: Volatility, Financial Risk & Investment Risk
Neogen Corp (NEOG) currently shows a risk assessment score of 5.27, placing it 83rd out of 204 in the Healthcare Equipment & Supplies industry. The stock's beta of 1.82 indicates higher volatility compared to the S&P 500. Key metrics include a 240-day maximum drawdown of +27.71% and a 240-day volatility of +62.66%.
Neogen Corp (NEOG) Earnings Forecast: Future EPS & Revenue Growth Estimates
Neogen Corp (NEOG) currently holds an earnings forecast score of 7.50, ranking 135th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $7.25, with a majority recommending a "Buy" trend. The company's expected revenue for the next quarter is $212.35 million, and its EPS for the upcoming quarter is projected to be $0.06.
Neogen Corp (NEOG) Institutional Confidence
Neogen Corp (NEOG) has a strong institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. Institutional holdings increased by 6.66% quarter-over-quarter, with Ron Baron being the largest shareholder. Major institutional investors include BlackRock, Clarkston Capital Partners, and T. Rowe Price, with varying changes in their shareholdings.
Neogen Corp Stock (US6404911066): Quiet Day, Stock in Focus at Monday's Close
Neogen Corp shares were in focus on June 15, 2026, but without any verified new market triggers, analyst updates, earnings releases, or sector catalysts. The stock is identified as a "quiet-day name" driven by the company's operating story and prior disclosures, rather than new headlines. For U.S. retail investors, this type of session highlights the importance of the absence of new information, making structural factors like food and animal safety product demand and customer retention key drivers.
Neogen updates Igenity Beef with new traits
Neogen's genomics division has updated its Igenity Beef genomic profile, specifically for commercial cow-calf producers. The new features include a BRD (Bovine Respiratory Disease) score, a Sustainability Index with Sustainability Extra Dollars, and a Methane Emission Intensity Index. These additions aim to help producers improve genetic resistance to BRD, enhance efficiency, and contribute to sustainability in beef production.
NEOGEN (NEOG) CAO has shares withheld to cover RSU tax obligations
NEOGEN's Chief Accounting Officer, John Patrick Moylan, had 2,553 shares withheld to cover tax obligations related to the vesting of restricted stock units (RSUs) on June 3, 2026. This transaction, valued at $8.75 per share, was a non-market disposition for tax withholding purposes. Following this, Moylan directly holds 23,571 shares of NEOGEN stock.
Amy M. Rocklin sells 87,681 NEOG shares (NASDAQ:NEOG)
Amy M. Rocklin reported the sale of 87,681 shares of NEOGEN CORP (NASDAQ:NEOG) common stock on May 29, 2026, generating proceeds of $805,153.08. This transaction was disclosed via a Form 144 SEC filing, which records affiliate sales, and also notes an option granted date of June 2, 2025. The filing indicates a neutral impact and sentiment on the stock.
NEOG - Neogen Corp Stock Price and Quote
This article provides a detailed financial overview of Neogen Corp (NEOG), including its stock performance, key financial metrics, analyst ratings, and recent news. It highlights the company's valuation, insider transactions, and upcoming earnings reports, offering a comprehensive snapshot for investors.
Assessing Neogen (NEOG) Valuation After Earnings Beat But Slower Growth Than Peers
Neogen (NEOG) reported earnings and revenue that exceeded analyst estimates, but its revenue declined 4.4% year-on-year and lagged behind peers. Despite this, the stock is considered 22.5% undervalued with a narrative fair value of $12.00, driven by portfolio simplification, a focus on core businesses, and investments in R&D. However, potential risks include integration issues with 3M Food Safety assets and ongoing weakness in Animal Safety.
[144] NEOGEN CORP SEC Filing
This article reports on a Form 144 SEC filing by NEOGEN CORP (NEOG) for a proposed sale of securities. The filing indicates a sale of 87,681 shares of common stock with an aggregate market value of $805,153.69, acquired via stock option grant on August 15, 2025, and scheduled for sale on May 29, 2026, through Fidelity Brokerage Services LLC on NASDAQ. The document provides detailed information required by Rule 144, including filer and issuer information, specifics of the securities to be sold, and a representation that no material adverse information is known but not publicly disclosed.
Neogen Corp stock (US6404911066): share jumps after strong quarterly update and integration progress
Neogen Corp's stock experienced a jump following a strong quarterly report that highlighted solid growth in food safety testing and significant progress in integrating the acquired 3M food safety business. The company's focus on food safety solutions and animal health products, alongside strategic acquisitions and ongoing innovation, are key drivers. Investors are closely watching the company's ability to convert revenue growth into sustained margin expansion as it continues to integrate the 3M assets and optimize its global footprint.
Neogen (NEOG) officer exercises 35,183 shares, settles tax with stock
Former Chief Legal Officer of Neogen (NEOG), Amy M. Rocklin, exercised 35,183 Restricted Stock Units, converting them into common stock at $9.29 per share. To cover tax obligations, 10,241 shares were withheld. Following these transactions, Rocklin directly holds 82,182 shares of NEOGEN CORP Common Stock.
Neogen Corp stock (US6404911066): integration progress and growth drivers in food and animal safety
Neogen Corp (NEOG) is actively integrating its acquired 3M food safety business, a process that brings both costs and revenue synergies. The company's core business revolves around food and animal safety diagnostics, with major revenue drivers including diagnostic kits, genomics services, and veterinary products. Neogen's growth is driven by increasing regulatory demands, consumer expectations for quality, and global trends in protein consumption and biosecurity.
Neogen Corp stock (US6404911066): what rising short interest means for investors
Neogen Corp (NEOG) shares have seen increased short interest, reaching over 5% of its free float, as the company continues to integrate its 3M acquisition and expand its product portfolio on Nasdaq. The company, a specialist in food and animal safety diagnostics, faces challenges from competition, integration of acquisitions, and the need for continuous innovation, despite benefiting from long-term regulatory and consumer trends in its markets. Investors are divided on the stock's near-term trajectory, with rising short interest signaling potential volatility or downside.
Clarkston Capital Group discloses 2.2M shares of Neogen (NEOG)
Clarkston Capital Group, along with Clarkston Capital Partners, LLC, Clarkston Companies, Inc., Jeffrey A. Hakala, and Gerald W. Hakala, has disclosed beneficial ownership of 2,204,788 shares of Neogen Corporation (NEOG). This represents a 1.01% stake in the company, based on 217,673,041 shares outstanding as of February 28, 2026. The shares are held in discretionary client accounts managed by Clarkston Capital Partners.
Neogen Corp stock (US6404911066): Recent 1.95% gain amid volatility
Neogen Corp (NEOG) shares recently gained 1.95% to $5.22 on July 25, 2025, extending a five-day winning streak despite a prior two-week loss, with analysts monitoring upcoming earnings on July 29, 2025. The company specializes in diagnostic test kits for food safety and animal health, serving vital roles in the US agriculture and food processing sectors. While showing short-term momentum, potential declines are forecasted ahead of the earnings report, highlighting market volatility.
Wall Street Zen Upgrades Neogen (NASDAQ:NEOG) to "Buy"
Wall Street Zen upgraded Neogen (NASDAQ:NEOG) to a "buy" rating from "hold" on Saturday. The upgrade comes after Neogen reported stronger-than-expected quarterly results, with EPS of $0.09 against estimates of $0.04 and revenue of $211.2 million, surpassing forecasts despite a 4.4% year-over-year decline. Institutional investors continue to hold a significant stake in Neogen, owning 96.73% of outstanding shares.
Do Neogen’s New Executive Equity Grants Reveal a Deeper Strategic Shift at NEOG?
Neogen's Chief Legal Officer recently received substantial equity grants, coinciding with the company facing declining sales, shrinking returns on capital, and ongoing EBITDA losses. While these grants don't immediately alter the investment narrative, they highlight the company's struggle to achieve sustainable cash generation amidst operational challenges. The key focus for investors remains on whether cost control and integration efforts can improve margins and alleviate financing concerns.
NEOGEN CORP (NEOG) officer exercises RSUs, uses shares for taxes
NEOGEN CORP's Chief Accounting Officer, John Patrick Moylan, reported exercising 4,558 Restricted Stock Units (RSUs) into common shares. Concurrently, 1,568 common shares were disposed of to cover tax obligations, not through an open-market sale. Following these transactions, Moylan directly holds 18,905 shares of NEOGEN common stock.
FY2026 Earnings Estimate for Neogen Issued By Zacks Research
Zacks Research has updated its earnings estimates for Neogen, raising the FY2026 EPS to $0.22 while simultaneously cutting near-term estimates and lowering FY2027/FY2028 forecasts, indicating a mixed outlook. Despite a recent earnings beat with $0.09 EPS on $211.2M revenue, the company experienced a 4.4% year-over-year revenue decline and a significant negative net margin. Neogen currently holds a "Hold" consensus rating with a target price of $10.67, trades around $9.09, and is largely institutionally owned (96.7%).
Neogen (NASDAQ: NEOG) awards shares and options to Chief Legal Officer
Neogen (NASDAQ: NEOG) Chief Legal Officer Stacey Jennifer Evans was granted 39,349 shares of common stock and 89,520 options to buy common stock on May 1, 2026. The shares were valued at $9.53 per share, and the options have an exercise price of $9.53 per share, expiring on May 1, 2036. Both the options and related RSUs will vest in equal annual installments over three years, indicating a multi-year compensation grant rather than an open-market transaction.
Neogen and Baxter Shares Are Falling, What You Need To Know
Shares of Neogen (NEOG) and Baxter (BAX) experienced declines following a renewed incident involving Iran and the UAE, which reignited concerns about input cost inflation and global supply chain disruptions for med-tech manufacturing due to rising crude oil prices. The medical device sector also faces increased freight costs and potential deferrals of elective procedures. Neogen shares fell 4.7% but are up 29.2% year-to-date, while Baxter shares dropped 3.2%.
Zacks Research Brokers Lower Earnings Estimates for Neogen
Zacks Research has updated its earnings estimates for Neogen (NASDAQ:NEOG), lowering the Q4 2026 EPS forecast from $0.07 to $0.03. This revision comes despite Neogen recently beating consensus earnings estimates for its latest quarter, reporting $0.09 EPS on $211.2 million revenue, though revenue marked a 4.4% year-over-year decline. The company currently holds an average "Hold" rating from analysts with an average price target of $10.67.
Vanguard Capital Management holds 11.16M shares in Neogen (NEOG)
Vanguard Capital Management has reported a beneficial ownership of 11.16 million shares in Neogen (NEOG), representing 5.13% of the company's common stock as of March 31, 2026. This disclosure was made through a Schedule 13G filing, indicating a passive investment. Vanguard holds sole voting power over approximately 1.6 million shares and sole dispositive power over all 11.16 million shares.
Vanguard Portfolio Management reports 12.9M Neogen shares (NEOG) on 13G
Vanguard Portfolio Management has reported a beneficial ownership of 12,916,330 shares of Neogen Corp (NEOG), representing 5.93% of the common stock as of March 31, 2026. This disclosure was made via a Schedule 13G filing, indicating a passive institutional stake. Vanguard maintains sole dispositive power over these shares, with a small portion having sole voting power, and affiliated investment vehicles exercise dispositive authority.
Neogen (NASDAQ:NEOG) Stock Crosses Above Two Hundred Day Moving Average - Should You Sell?
Neogen (NASDAQ:NEOG) stock recently crossed above its two hundred day moving average, with shares trading at $9.34. The company's latest quarterly results beat analyst estimates for EPS and revenue, but revenue was down year-over-year, and the company still faces profitability pressures with a negative net margin and P/E. Analysts currently have a consensus "Hold" rating on the stock with an average target price of $10.67, while institutional investors have actively bought and sold shares.
Is AOAC-Certified Rapid Listeria Test Altering The Investment Case For Neogen (NEOG)?
Neogen Corporation's new AOAC-certified rapid Listeria test could enhance its appeal to food manufacturers seeking faster contamination control. While this validation supports the demand for testing, the company's investment narrative still hinges on resolving integration issues, overcoming soft market conditions, and achieving profitability by 2029. Despite the positive news, analysts remain divided on the company's prospects, with some anticipating continued revenue decline and no profits until 2029.
NEOG Price Today: Neogen Corp. Stock Price, Quote & Chart | MEXC
This article provides the current stock price, key market data, and recent performance of Neogen Corp. (NEOG). It details how to buy NEOG stock on MEXC, describes the company's business in food and animal safety, and answers frequently asked questions about its financial metrics and market classification.
Neogen’s Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification
Neogen Corporation announced that its Molecular Detection Assay - Listeria Right Now™ rapid environmental monitoring test has received AOAC® Performance Tested Methods℠ (PTM) certification. This certification validates the test's performance for enrichment-free detection of viable and non-viable Listeria species on stainless steel surfaces. The technology aims to provide food manufacturers with a faster and more reliable method to identify contamination risks and strengthen their food safety programs.
Neogen (NEOG) Achieves Certification for Rapid Listeria Testing Method
Neogen Corp (NEOG) has successfully obtained AOAC Performance Tested Methods certification for its rapid Listeria testing assay, Listeria Right Now, designed for environmental monitoring on stainless steel surfaces. This certification represents a significant advancement in food safety, enabling quicker detection without traditional bacterial culture growth. Despite a strong GF Score™ of 74 indicating potential for long-term returns, the company faces challenges in revenue growth, although recent insider buying suggests confidence in its future performance.
Crude Oil Surges 3%; Neogen Shares Fall After Q3 Results
U.S. stocks saw broad gains with the Dow Jones, NASDAQ, and S&P 500 all trading higher. Neogen Corp shares fell by 3% despite beating Q3 earnings and sales estimates. Meanwhile, crude oil surged over 3%, and several other equities experienced significant movements based on company news and financial results.
Neogen’s Listeria Right Now™ Test Receives AOAC® Performance Tested Methods℠ Certification
Neogen Corporation announced its Molecular Detection Assay - Listeria Right Now™ rapid environmental monitoring test has received AOAC® Performance Tested Methods℠ (PTM) certification. This certification validates the test's performance for the enrichment-free detection of viable and non-viable Listeria species on stainless steel surfaces, offering a faster and more efficient method for food safety monitoring. The test provides actionable results in about two hours, enabling food manufacturers to quickly identify contamination risks and strengthen their environmental monitoring workflows.
Round Rock Advisors LLC Purchases 131,684 Shares of Neogen Corporation $NEOG
Round Rock Advisors LLC significantly increased its stake in Neogen Corporation (NASDAQ:NEOG) by 520.8% in the fourth quarter, purchasing an additional 131,684 shares to bring its total holding to 156,967 shares valued at approximately $1.10 million. Despite a consensus "Hold" rating from analysts, some firms have recently raised their price targets for Neogen. The company beat Q4 earnings estimates with $0.09 EPS and $211.2 million in revenue, though it reported a negative net margin of 69.93%.
Neogen Corp stock (US6404911066): Is its animal health focus strong enough to unlock new upside?
Neogen Corp (US6404911066) specializes in animal health and food safety diagnostics and genomics, addressing rising global food demands and agricultural pressures. The company's business model focuses on recurring revenue from diagnostic test kits and genomic tools, serving livestock production, food processing, and expanding into pet health and crop protection. Neogen's strategy aligns with precision agriculture and biosecurity needs, leveraging R&D, partnerships, and acquisitions to maintain a competitive edge despite competition from larger industry players.
Neogen Corporation 8-K SEC Filing April 20, 2026 – Key Entity Information, Trading Symbol, and Nasdaq Listing
Neogen Corporation filed an 8-K with the SEC on April 20, 2026, detailing investor facility tours and significant progress in its Petrifilm manufacturing. The company has completed operational qualifications for several Petrifilm single kit units and is advancing to performance qualifications, indicating enhanced production capabilities. This transparency aims to positively influence investor sentiment, with potential for share price impact upon successful validation.
Neogen (NEOG) plans investor tours to showcase Petrifilm validation progress
Neogen Corporation (NEOG) announced it will host two investor tours at its Petrifilm manufacturing facility in Lansing, Michigan, on April 20 and 21, 2026. The company will showcase progress on its Petrifilm validation efforts, specifically that it has successfully completed multiple operational qualifications for certain single kit units and is advancing to performance qualifications. This update was disclosed in an 8-K filing, detailing the technical validation and investor outreach plans.
Neogen schedules investor tours at Lansing facility, updates on Petrifilm validation By Investing.com
Neogen Corporation announced investor tours at its Lansing, Michigan Petrifilm manufacturing facility, scheduled for Monday and Tuesday. This announcement comes as Neogen's stock has seen a significant 117% surge over the last year. The company will also provide updates on the ongoing validation process for Petrifilm single kit units during these tours.
Neogen to host investor tours as Petrifilm SKUs complete operational qualifications
Neogen (NEOG) announced planned investor tours of its Lansing Petrifilm facility on April 20-21, 2026. The company also disclosed the completion of multiple operational qualifications for various Petrifilm single kit units (SKUs) and is moving forward with performance qualifications. This information will be shared with investors during the tours.
CapEx per share of Neogen Corp – FWB:NG2
This article provides financial data for Neogen Corp (FWB:NG2), specifically focusing on its CapEx per share. It presents a table showing the period, value, change, and percentage change for this metric, with data sourced from ICE Data Services and FactSet.
Neogen Reshapes Portfolio Around Food Safety With Divestitures And Job Cuts
Neogen is undergoing a significant portfolio reshaping, divesting its Genomics and Cleaners and Disinfectants businesses and reducing its global headcount by 10%. These actions aim to focus the company on its core Food Safety segment and streamline operations. Investors are encouraged to monitor how these changes impact future segment margins, free cash flow, and the company's path to profitability.
